scroll to top
0

Mobile Menu

Header Layout

EBSCO Auth Banner

Let's find your institution. Click here.

Page title

Advanced Search Results For "TYPE 2 diabetes"

1 - 10 of 327,625 results for
 "TYPE 2 diabetes"
Results per page:

Association of gene polymorphisms with body weight changes in prediabetic patients.

Publication Type:Academic Journal

Source(s):Molecular biology reports [Mol Biol Rep] 2022 Jun; Vol. 49 (6), pp. 4217-4224. Date of Electronic Publication: 2022 Mar 15.

Abstract:Background: Recent research has demonstrated that Type 2 Diabetes (T2D) risk is influenced by a number of common polymorphisms, including MC4R rs17782313, PPARG rs1801282, and TCF7L2 rs7903146. Knowledge of the association between these single nucleoti...

View details

[Effect of electroacupuncture at "Tianshu" (ST25) on the regulation of nitrergic neurons in different intestinal segments in streptozotocin induced type 2 diabetic rats].

Publication Type:Academic Journal

Source(s):Zhen ci yan jiu = Acupuncture research [Zhen Ci Yan Jiu] 2022 Sep 25; Vol. 47 (9), pp. 785-92.

Abstract:Objective: To observe the effect of electroacupuncture (EA) at "Tianshu" (ST25) on nitrergic neurons in jejunum and distal colon in type 2 diabetic rats, so as to explore its mechanism of regulating different intestinal segments.Methods: Twenty-four SD...

View details

Association of skin autofluorescence with low bone density/osteoporosis and osteoporotic fractures in type 2 diabetes mellitus.

Publication Type:Academic Journal

Source(s):Journal of diabetes [J Diabetes] 2022 Sep; Vol. 14 (9), pp. 571-585. Date of Electronic Publication: 2022 Sep 04.

Abstract:Background: Advanced glycation end products (AGEs) that abnormally accumulate in diabetic patients have been reported to damage bone health. We aimed to investigate the association between skin autofluorescence (SAF)-AGE age (SAF - AGEs × age/100) and ...

View details

Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.

Publication Type:Academic Journal

Source(s):Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Oct; Vol. 24 (10), pp. 1950-1956. Date of Electronic Publication: 2022 Jun 28.

Abstract:Aims: To test the hypothesis that the reduction in urinary kidney injury molecule-1 (KIM-1) observed with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin is mediated through its effects on urine albumin to creatinine ratio (UACR) and...

View details

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.

Publication Type:Academic Journal

Source(s):Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Sep 23; Vol. 21 (1), pp. 194. Date of Electronic Publication: 2022 Sep 23.

Abstract:Background: Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided by multivariable predicted ris...

View details

Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin.

Publication Type:Academic Journal

Source(s):Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2022 Sep; Vol. 15 (9), pp. 1107-1117. Date of Electronic Publication: 2022 Sep 05.

Abstract:Introduction: Metformin has been recognized as the first-choice drug for type 2 diabetes mellitus (T2DM). The potency of metformin in the treatment of type 2 diabetes has always been in the spotlight and shown significant individual differences. Based ...

View details

Network pharmacology and molecular docking approaches to elucidate the potential compounds and targets of Saeng-Ji-Hwang-Ko for treatment of type 2 diabetes mellitus.

Publication Type:Academic Journal

Source(s):Computers in biology and medicine [Comput Biol Med] 2022 Oct; Vol. 149, pp. 106041. Date of Electronic Publication: 2022 Aug 25.

Abstract:Background: Saeng-Ji-Hwang-Ko (SJHK) is a traditional Korean medicine formula derived from Donguibogam, a classic medical textbook, published in 1613. It is described as a general treatment for So-gal (wasting-thirst, ) known as type 2 diabetes mellitu...

View details

Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013-2019.

Publication Type:Academic Journal

Source(s):Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2022 Sep; Vol. 39 (9), pp. e14866. Date of Electronic Publication: 2022 May 16.

Abstract:Aims: To analyse the prevalence of prescribed medications among people with type 2 diabetes, their relationship to HbA1c levels and transitions between medications.Methods: The data included all 18- to 85-year-old adults with type 2 diabetes (identifie...

View details

Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approach.

Publication Type:Academic Journal

Source(s):Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Aug 01; Vol. 69, pp. 128782. Date of Electronic Publication: 2022 May 07.

Abstract:11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) has been identified as the primary enzyme responsible for the activation of hepatic cortisone to cortisol in specific peripheral tissues resulting in the concomitant antagonism of insulin action within thes...

View details

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.

Publication Type:Academic Journal

Source(s):International journal of molecular sciences [Int J Mol Sci] 2022 Aug 09; Vol. 23 (16). Date of Electronic Publication: 2022 Aug 09.

Abstract:Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechan...

View details

banner_970x250 (970x250)

sponsored